Sernova Opens the Market
2022年6月3日 - 12:00AM
PR Newswire (Canada)
TORONTO, June 2, 2022
/CNW/ - Dr. Philip Toleikis,
President and Chief Executive Officer, Sernova Corp. (TSXV: SVA)
and his team joined Tanya Rowntree,
Global Head of Client Success, Toronto Stock Exchange (TSX), to
celebrate the company's graduation from TSX Venture Exchange to
Toronto Stock Exchange and open the market.
Sernova Corp is a clinical-stage biotechnology company
developing regenerative therapeutic technologies to deliver a
'functional cure' for chronic diseases, including insulin-dependent
diabetes, thyroid disease, and blood disorders like hemophilia A.
An ongoing Phase I/II study at the University
of Chicago has treated the first 6 patients with type 1
diabetes using its implantable Cell Pouch™ therapy device. The
longest patient has now achieved 25 months with no insulin
injections needed and a second patient has been insulin independent
for over seven months. Sernova and Evotec recently entered into an
option and licensing partnership to develop an implantable
off-the-shelf iPSC-based beta cell replacement therapy to provide
Sernova an unlimited supply of insulin-producing cells for use with
its Cell Pouch System to treat potentially millions of patients
with insulin-dependent diabetes.
Date:
|
Thursday, June 2,
2022
|
|
|
Time:
|
9:00am -
9:30am
|
|
|
Place:
|
120 Adelaide St
W.
|
SOURCE Toronto Stock Exchange
Copyright 2022 Canada NewsWire
Sernova (TSXV:SVA)
過去 株価チャート
から 5 2024 まで 6 2024
Sernova (TSXV:SVA)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about Sernova Corp (トロントベンチャー取引所): 0 recent articles
その他のToronto Stock Exchangeニュース記事